Clicky

Emergent Biosolutions, Inc.(EBS)

Description: Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company's development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, based on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.


Keywords: Medicine Pharmaceutical Drugs Solid Tumors Vaccines Rheumatoid Arthritis Monoclonal Antibody Influenza Vaccination Lotion FDA Inflammatory Bowel Disease Chronic Lymphocytic Leukemia Decontamination Specialized Products Blood Plasma Host Disease Graft Versus Host Disease Lymphocytic Leukemia Biological Warfare Biodefense Monkeypox Chemical Warfare Agents Biomedical Advanced Research And Development Authority Anthrax Chemical Warfare Poxviruses Anthrax Vaccines Emergent Biosolutions Preclinical

Home Page: www.emergentbiosolutions.com

EBS Technical Analysis

400 Professional Drive
Gaithersburg, MD 20879
United States
Phone: 240 631 3200


Officers

Name Title
Mr. Robert G. Kramer Sr. CEO, Pres & Exec. Director
Mr. Richard S. Lindahl Exec. VP, CFO & Treasurer
Mr. Adam R. Havey Exec. VP & COO
Mr. Atul Saran Exec. VP & Chief Strategy and Devel. Officer
Mr. Robert G. Burrows VP of Investor Relations
Ms. Jennifer L. Fox Exec. VP of External Affairs, Gen. Counsel & Corp. Sec.
Ms. Coleen Glessner Exec. VP of Global Quality and Ethics & Compliance
Ms. Lynn Kieffer VP of Corp. Communications
Ms. Katherine Strei Exec. VP of HR & Chief HR Officer

Exchange: NYSE

Country: US

Currency: US Dollar ($)

Forward PE: 7.9428
Trailing PE: 15.8313
Price-to-Book MRQ: 0.41
Price-to-Sales TTM: 0.3672
IPO Date: 2006-11-15
Fiscal Year End: December
Full Time Employees: 2416
Back to stocks